Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zp17: sourced facts only. name: "Zp17 illustrated superior STING degradation activity and exhibited significantly lower cytotoxicity compared to SP23 in vitro." [PMID:42372458]; target: "Zp17 illustrated superior STING degradation activity and exhibited significantly lower cytotoxicity compared to SP23 in vitro." [PMID:42372458]; developer: "Collaborative Innovation Center of Henan Province for Green Manufacturing of Fine Chemicals, Key Laboratory of Green Chemical Media and Reactions, Ministry of Education, Henan Key Laboratory of Organic Functional Molecule and Drug Innovation, School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang, Henan 453007, PR China." [PMID:42372458]; modality: "Collectively, compound Zp17 warrants further investigation as PROTAC degrader of STING." [PMID:42372458]; stage: "In mouse acute kidney injury (AKI) model, Zp17 effectively alleviated renal function impairment induced by cisplatin." [PMID:42372458]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zp17.